EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?

Anna Lia Asti iD

International Journal of Molecular Sciences · 17.06.2026 · 27 (12) · 5460

DOI: 10.3390/ijms27125460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.06.2026. Verfasst von Anna Lia Asti. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum, Università di Bologna, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Antimicrobial Cationic Peptides. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Physiologically produced circulating β-amyloid (Aβ) exerts critical physiological functions. Although Aβ is a key player in Alzheimer’s disease (AD), it may initially be beneficial at the onset of infection. As an evolutionary conserved antimicrobial peptide (AMP), Aβ contributes to innate immune defense against pathogens. Host defense peptides such as Aβ and human cathelicidin (LL-37) not only kill pathogens through their antimicrobial activity but also exhibit high affinity for bacterial lipopolysaccharides (LPSs) and membrane receptors. LL-37, which is upregulated in the brain, binds to Aβ, modulating its aggregation; Aβ and LL-37 are protective under physiological conditions, but during chronic infection or dysregulation, their interaction becomes toxic and contributes to AD pathology. Similarly to Aβ, LL-37 can induce neuroinflammation by stimulating human microglia to release inflammatory cytokines, such as TNF-α and IL-6. Neuroinflammation is essential for protecting the brain from pathogens—when prolonged, it drives pathological processes underlying AD, Parkinson’s disease (PD), and other neurodegenerative disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAntimicrobial Cationic PeptidesHumansCathelicidinsAlzheimer DiseaseAnimalsMicrogliaAntimicrobial PeptidesParkinson DiseaseImmunity, Innate

Stichwörter der Autor:innen

Alzheimer’s disease (AD)Parkinson’s disease (PD)aggregation-prone regions (ARPs)antimicrobial peptide (AMP)critical micelle concentration (CMC)hCAP18 cathelicidin (LL-37)lipopolysaccharide (LPS)β-amyloid (Aβ)

Substanzen

Amyloid beta-PeptidesCathelicidinsAntimicrobial Cationic PeptidesAntimicrobial Peptides

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum, Università di Bologna, 40126 Bologna, Italy.

ORCID-Profile: Anna Lia Asti

Zitieren

APA

Asti, A. L. (2026). β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?. International Journal of Molecular Sciences, 27(12), 5460. https://doi.org/10.3390/ijms27125460

Vancouver

Asti AL. β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?. International Journal of Molecular Sciences. 2026;27(12):5460. doi:10.3390/ijms27125460

BibTeX
@article{Asti2026,
  author = {Asti, Anna Lia},
  title = {β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5460},
  doi = {10.3390/ijms27125460}
}
Kostenlos starten →